Etelcalcetide

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hyperparathyroidism, Secondary

Conditions

Hyperparathyroidism, Secondary

Trial Timeline

Mar 25, 2014 → Jun 26, 2017

NCT ID

NCT02102204

About Etelcalcetide

Etelcalcetide is a phase 3 stage product being developed by Amgen for Hyperparathyroidism, Secondary. The current trial status is completed. This product is registered under clinical trial identifier NCT02102204. Target conditions include Hyperparathyroidism, Secondary.

What happened to similar drugs?

13 of 20 similar drugs in Hyperparathyroidism, Secondary were approved

Approved (13) Terminated (2) Active (7)

✅Cinacalcet HClKyowa KirinApproved

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅Alendronate 70mg weeklyMerckApproved

✅AMG 073AmgenApproved

✅DenosumabAmgenApproved

✅Sensipar® + Vitamin DAmgenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03969329	Phase 3	Recruiting	Dec 20, 2019	Jun 30, 2027	Secondary Hyperparathyroidism
NCT03795558	Phase 2	Completed	May 1, 2019	Mar 1, 2022	End Stage Renal Disease
NCT03633708	Phase 3	Recruiting	Apr 29, 2019	Jan 31, 2029	Secondary Hyperparathyroidism
NCT02833857	Phase 1	Completed	Mar 14, 2017	Oct 31, 2018	Chronic Kidney Disease, Secondary Hyperparathyroidism
NCT02102204	Phase 3	Completed	Mar 25, 2014	Jun 26, 2017	Hyperparathyroidism, Secondary
NCT01932970	Phase 3	Completed	Aug 12, 2013	Feb 14, 2017	Hyperparathyroidism, Secondary
NCT01785875	Phase 3	Completed	Jul 31, 2013	Jul 1, 2015	Hyperparathyroidism, Secondary

Competing Products

20 competing products in Hyperparathyroidism, Secondary

See all competitors

Product	Company	Stage	Hype Score
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
KHK7580 + KRN1493	Kyowa Kirin	Phase 2/3	38
KHK7580	Kyowa Kirin	Phase 1	29
KHK7580	Kyowa Kirin	Phase 1/2	32
KHK7580	Kyowa Kirin	Phase 3	40
KHK7580	Kyowa Kirin	Phase 3	40
Cinacalcet HCl	Kyowa Kirin	Approved	43
KHK7580 + Cinacalcet Hydrochloride	Kyowa Kirin	Phase 3	40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493	Kyowa Kirin	Phase 2	35
Paricalcitol + Calcitriol	AbbVie	Pre-clinical	18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo	AbbVie	Phase 3	40
Paricalcitol + Calcifediol	AbbVie	Approved	43
Paricalcitol + Darbepoetin alfa	AbbVie	Approved	43
Alendronate 70mg weekly	Merck	Approved	35
Cinacalcet + Placebo	Amgen	Phase 2	35
Cinacalcet + Placebo	Amgen	Phase 3	40
Etelcalcetide + Placebo	Amgen	Phase 1	29
Sensipar (Cinacalcet HCl)	Amgen	Phase 2	35
AMG 073 + Placebo	Amgen	Phase 3	40
cinacalcet	Amgen	Phase 3	40